Bartlett & CO. Wealth Management LLC Reduces Stake in Danaher Corporation $DHR

Bartlett & CO. Wealth Management LLC lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,494 shares of the conglomerate’s stock after selling 939 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Danaher were worth $13,934,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of Danaher during the 1st quarter valued at about $833,941,000. Invesco Ltd. boosted its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. grew its holdings in shares of Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after acquiring an additional 1,072,617 shares during the period. Generation Investment Management LLP raised its position in shares of Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock worth $651,515,000 after acquiring an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC boosted its position in shares of Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after purchasing an additional 722,636 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR opened at $198.05 on Wednesday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The company’s 50 day moving average is $199.55 and its 200 day moving average is $197.31. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market cap of $141.82 billion, a price-to-earnings ratio of 42.14, a PEG ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same period last year, the firm earned $1.72 EPS. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 11.20% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several recent research reports. Robert W. Baird raised their price objective on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. UBS Group lowered their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Bank of America cut their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a report on Tuesday, September 2nd. Finally, Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.